Corey Carter
Experienced in Bladder Cancer

Dr. Corey Carter

Hematology
Wrnmmcb
8901 Wisconsin Ave, 
Bethesda, MD 
Experienced in Bladder Cancer
Wrnmmcb
8901 Wisconsin Ave, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Corey Carter is a Hematologist in Bethesda, Maryland. Dr. Carter is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Bladder Cancer.

Specialties
Hematology
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Wrnmmcb
8901 Wisconsin Ave, Bethesda, MD 20889
Other Locations
Walter Reed National Military Medical Center
8901 Wisconsin Ave, Bethesda, MD 20889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)
Enrollment Status: Completed
Publish Date: November 18, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

76 Total Publications

Correlation of safety and efficacy of atezolizumab therapy across indications.
Correlation of safety and efficacy of atezolizumab therapy across indications.
Journal: Journal for immunotherapy of cancer
Published: October 18, 2024
Similar Doctors
Distinguished in Bladder Cancer
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology
Distinguished in Bladder Cancer
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

4320 Seminary Rd, 
Alexandria, VA 
 (12.0 miles away)
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeanny Aragon-Ching is an Oncologist and a Hematologist in Alexandria, Virginia. Dr. Aragon-Ching is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.

Advanced in Bladder Cancer
Dr. Saro Sarkisian
Hematology | Oncology
Advanced in Bladder Cancer
Dr. Saro Sarkisian
Hematology | Oncology

Frederick Health Medical Group LLC

1562 Opossumtown Pike, 
Frederick, MD 
 (34.7 miles away)
301-662-8477
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Saro Sarkisian is a Hematologist and an Oncologist in Frederick, Maryland. Dr. Sarkisian has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Chronic T-Cell Leukemia (CTCL), Colorectal Cancer, Familial Colorectal Cancer, and Pleuropulmonary Blastoma.

Advanced in Bladder Cancer
Dr. David Smith
Hematology
Advanced in Bladder Cancer
Dr. David Smith
Hematology

Bay Hematology Oncology P.A.

2977 4H Park Rd Ste 102, 
Centreville, MD 
 (56.5 miles away)
410-758-4030
Languages Spoken:
English
See accepted insurances

David Smith is a Hematologist in Centreville, Maryland. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Myelodysplastic Syndrome (MDS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carter's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile